Vectura has announced that it will receive a €5 million milestone now that Bayer AG has launched the Breelib nebulizer for Ventavis iloprost inhalation solution in Poland. Breelib is an adaptation of Vectura’s FOX handheld smart nebulizer, which Vectura acquired along with its developer, Activaero, in 2014.
In addition to the initial milestone, Vectura is eligible for annual milestones up to a total €5.75 million to be paid on the anniversaries of the first launch.
According to Vectura, the Breelib device offers flow rate and volume control and is designed specifically for delivery of Ventavis.
Vectura CEO James Ward-Lilley commented, “We are pleased to have supported Bayer in this collaboration enhancing drug delivery and ease of device usage for patients with pulmonary arterial hypertension. The launch of the Breelib device marks an important validation of Vectura’s mesh based handheld device technology using the FOX smart nebuliser. Breelib’s proprietary flow-rate and volume control system is also utilised in Vectura’s jet based AKITA nebuliser platforms. Vectura expects to increase the utilization of the mesh based nebuliser platforms with a number of further partnering collaborations.”
Read the Vectura press release.
